Correction: "Hepatitis C virus NS4B can suppress STING accumulation to evade innate immune responses" [Journal of Virology, 90, 1, (2016) (254-265)] doi 10.1128/JVI.01720-15;Hepatitis C virus NS4B can suppress STING accumulation to evade innate immune responses

Journal of Virology

Volumn 90, Issue 1, 2016, Pages 254-265

  Yi, Guanghui ^a   Wen, Yahong ^a   Shu, Chang ^b   Han, Qingxia ^c   Konan, Kouacou V ^c   Li, Pingwei ^b   Cheng Kao, C ^a  

^a INDIANA UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYCLIC GMP; NONSTRUCTURAL PROTEIN 4B; STIMULATOR OF INTERFERON GENE PROTEIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; NS4B PROTEIN, FLAVIVIRUS; VIRAL PROTEIN;

ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; HEPATITIS C VIRUS SUBTYPE 1B; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; INNATE IMMUNITY; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS REPLICATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE EVASION; IMMUNOLOGY; LIVER CELL; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

CELL LINE, TUMOR; GENOTYPE; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; MEMBRANE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84953875903     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01520-17     Document Type: Erratum

References (60)

1. Bartenschlager R, Lohmann V, Penin F. 2013. The molecular and structural basis of advanced antiviral therapy for hepatitisCvirus infection. Nat Rev Microbiol 11:482-496. http://dx.doi.org/10.1038/nrmicro3046.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982. http://dx.doi.org/10.1056/NEJMoa020047.
3. Smith DB, Bukh J, Kuiken C, MuerhoffAS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology 59:318-327. http://dx.doi.org/10.1002/hep.26744.
4. Kiser JJ, Flexner C. 2013. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol 53:427-449. http://dx.doi.org/10.1146/annurev-pharmtox-011112-140254.
5. Weng L, Hirata Y, Arai M, Kohara M, Wakita T, Watashi K, Shimotohno K, He Y, Zhong J, Toyoda T. 2010. Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype-specific manner. J Virol 84:11761-11770. http://dx.doi.org/10.1128/JVI.00638-10.
6. Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J 2014. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology 146: 812-821. http://dx.doi.org/10.1053/j.gastro.2013.11.009.
7. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, McHutchison JG, Subramanian M, Millington DM, Kelley RI, Patel K. 2012. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56:49-56. http://dx.doi.org/10.1002/hep.25631.
8. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. 2011. Differential efficacy of protease inhibitors againstHCVgenotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 141:1067-1079. http://dx.doi.org/10.1053/j.gastro.2011.06.004.
9. Lindenbach BD, Rice CM. 2005. Unravelling hepatitis C virus replication from genome to function. Nature 436:933-938. http://dx.doi.org/10.1038/nature04077.
10. Moradpour D, Penin F. 2013. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 369:113-142. http://dx.doi.org/10.1007/978-3-642-27340-7_5.
11. Horner SM, Gale M, Jr. 2013. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 19:879-888. http://dx.doi.org/10.1038/nm.3253.
12. Fredericksen B, Akkaraju GR, Foy E, Wang C, Pflugheber J, Chen ZJ, Gale M, Jr. 2002. Activation of the interferon-beta promoter during hepatitisCvirusRNAreplication. Viral Immunol 15:29-40. http://dx.doi.org/10.1089/088282402317340215.
13. Kanda T, Steele R, Ray R, Ray RB. 2007. Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes. J Virol 81:12375-12381. http://dx.doi.org/10.1128/JVI.01695-07.
14. Randall RE, Goodbourn S. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89:1-47. http://dx.doi.org/10.1099/vir.0.83391-0.
15. Gonzalez-Navajas JM, Lee J, David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat Rev Immunol 12:125-135. http://dx.doi.org/10.1038/nri3133.
16. Foy E, Li K, Wang C, Sumpter R, Jr, Ikeda M, Lemon SM, Gale M, Jr. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300:1145-1148. http://dx.doi.org/10.1126/science.1082604.
17. Foy E, Li K, Sumpter R, Jr, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 102:2986-2991. http://dx.doi.org/10.1073/pnas.0408707102.
18. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Jr, Lemon SM. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102:2992-2997. http://dx.doi.org/10.1073/pnas.0408824102.
19. Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M. 2013. Hepatitis C virus NS4B protein targets STING and abrogates RIGI-mediated type I interferon-dependent innate immunity. Hepatology 57: 46-58. http://dx.doi.org/10.1002/hep.26017.
20. Ding Q, Cao X, Lu J, Huang B, Liu YJ, Kato N, Shu HB, Zhong J. 2013. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J Hepatol 59:52-58. http://dx.doi.org/10.1016/j.jhep.2013.03.019.
21. Gouttenoire J, Montserret R, Paul D, Castillo R, Meister S, Bartenschlager R, Penin F, Moradpour D. 2014. Aminoterminal amphipathic alpha-helix AH1 of hepatitis C virus nonstructural protein 4B possesses a dual role in RNA replication and virus production. PLoS Pathog 10: e1004501. http://dx.doi.org/10.1371/journal.ppat.1004501.
22. Han Q, Aligo J, Manna D, Belton K, Chintapalli SV, Hong Y, Patterson RL, van Rossum DB, Konan KV. 2011. Conserved GXXXG-and S/T-like motifs in the transmembrane domains of NS4B protein are required for hepatitis C virus replication. J Virol 85:6464-6479. http://dx.doi.org/10.1128/JVI.02298-10.
23. Paredes AM, Blight KJ. 2008. A genetic interaction between hepatitis C virus NS4B and NS3 is important for RNA replication. J Virol 82:10671-10683. http://dx.doi.org/10.1128/JVI.00875-08.
24. Paul D, Romero-Brey I, Gouttenoire J, Stoitsova S, Krijnse-Locker J, Moradpour D, Bartenschlager R. 2011. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. J Virol 85:6963-6976. http://dx.doi.org/10.1128/JVI.00502-11.
25. Han Q, Manna D, Belton K, Cole R, Konan KV. 2013. Modulation of hepatitis C virus genome encapsidation by nonstructural protein 4B. J Virol 87:7409-7422. http://dx.doi.org/10.1128/JVI.03523-12.
26. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE. 2011. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478:515-518. http://dx.doi.org/10.1038/nature10429.
27. Woodward JJ, Iavarone AT, Portnoy DA. 2010. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 328:1703-1705. http://dx.doi.org/10.1126/science.1189801.
28. Burdette DL, Vance RE. 2013. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol 14:19-26. http://dx.doi.org/10.1038/ni.2491.
29. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786-791. http://dx.doi.org/10.1126/science.1232458.
30. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ. 2013. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339:826-830. http://dx.doi.org/10.1126/science.1229963.
31. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J, Hornung V. 2013. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature 498:380-384. http://dx.doi.org/10.1038/nature12306.
32. Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, Hayakawa Y, Hammond MC, Vance RE. 2013. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 3:1355-1361. http://dx.doi.org/10.1016/j.celrep.2013.05.009.
33. Gao P, Ascano M, Wu Y, Barchet W, Gaffney BL, Zillinger T, Serganov AA, Liu Y, Jones RA, Hartmann G, Tuschl T, Patel DJ. 2013. Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153:1094-1107. http://dx.doi.org/10.1016/j.cell.2013.04.046.
34. Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ. 2013. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 51:226-235. http://dx.doi.org/10.1016/j.molcel.2013.05.022.
35. Li X, Shu C, Yi G, Chaton CT, Shelton CL, Diao J, Zuo X, Kao CC, Herr AB, Li P. 2013. Cyclic GMP-AMP synthase is activated by doublestranded DNA-induced oligomerization. Immunity 39:1019-1031. http://dx.doi.org/10.1016/j.immuni.2013.10.019.
36. Ablasser A, Schmid-Burgk JL, Hemmerling I, Horvath GL, Schmidt T, Latz E, Hornung V. 2013. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503:530-534. http://dx.doi.org/10.1038/nature12640.
37. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76: 13001-13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014.2002.
38. Yi G, Deval J, Fan B, Cai H, Soulard C, Ranjith-Kumar CT, Smith DB, Blatt L, Beigelman L, Kao CC. 2012. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother 56:830-837. http://dx.doi.org/10.1128/AAC.05438-11.
39. Yi G, Brendel VP, Shu C, Li P, Palanathan S, Cheng Kao C. 2013. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One 8:e77846. http://dx.doi.org/10.1371/journal.pone.0077846.
40. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
41. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA. 2010. Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53:7202-7218. http://dx.doi.org/10.1021/jm100863x.
42. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, II, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi.org/10.1038/nature08960.
43. Parvatiyar K, Zhang Z, Teles RM, Ouyang S, Jiang Y, Iyer SS, Zaver SA, Schenk M, Zeng S, Zhong W, Liu ZJ, Modlin RL, Liu YJ, Cheng G. 2012. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol 13:1155-1161. http://dx.doi.org/10.1038/ni.2460.
44. Abdul-Sater AA, Tattoli I, Jin L, Grajkowski A, Levi A, Koller BH, Allen IC, Beaucage SL, Fitzgerald KA, Ting JP, Cambier JC, Girardin SE, Schindler C. 2013. Cyclic-di-GMP and cyclic-di-AMP activate the NLRP3 inflammasome. EMBO Rep 14:900-906. http://dx.doi.org/10.1038/embor.2013.132.
45. Tanaka Y, Chen ZJ. 2012. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal 5:ra20. http://dx.doi.org/10.1126/scisignal.2002521.
46. Sun W, Li Y, Chen L, Chen H, You F, Zhou X, Zhou Y, Zhai Z, Chen D, Jiang Z. 2009. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc Natl Acad Sci U S A 106:8653-8658. http://dx.doi.org/10.1073/pnas.0900850106.
47. Li E, Wimley WC, Hristova K. 2012. Transmembrane helix dimerization: beyond the search for sequence motifs. Biochim Biophys Acta 1818: 183-193. http://dx.doi.org/10.1016/j.bbamem.2011.08.031.
48. Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, Sun L, Chen ZJ. 2013. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341:903-906. http://dx.doi.org/10.1126/science.1240933.
49. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. 2013. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341:1390-1394. http://dx.doi.org/10.1126/science.1244040.
50. Schoggins JW, MacDuffDA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, Mar KB, Richardson RB, Ratushny AV, Litvak V, Dabelic R, Manicassamy B, Aitchison JD, Aderem A, Elliott RM, Garcia-Sastre A, Racaniello V, Snijder EJ, Yokoyama WM, Diamond MS, Virgin HW, Rice CM. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505:691-695. http://dx.doi.org/10.1038/nature12862.
51. Ishikawa H, Barber GN. 2008. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455:674-678. http://dx.doi.org/10.1038/nature07317.
52. Zhong B, Yang Y, Li S, Wang YY, Li Y, Diao F, Lei C, He X, Zhang L, Tien P, Shu HB. 2008. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29:538-550. http://dx.doi.org/10.1016/j.immuni.2008.09.003.
53. Ishikawa H, Ma Z, Barber GN. 2009. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461:788-792. http://dx.doi.org/10.1038/nature08476.
54. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, Bernal-Rubio D, Shabman RS, Simon V, Rodriguez-Madoz JR, Mulder LC, Barber GN, Fernandez-Sesma A. 2012. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog 8:e1002934. http://dx.doi.org/10.1371/journal.ppat.1002934.
55. Nazmi A, Mukhopadhyay R, Dutta K, Basu A. 2012. STING mediates neuronal innate immune response following Japanese encephalitis virus infection. Sci Rep 2:347. http://dx.doi.org/10.1038/srep00347.
56. Sun L, Xing Y, Chen X, Zheng Y, Yang Y, Nichols DB, Clementz MA, Banach BS, Li K, Baker SC, Chen Z. 2012. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One 7:e30802. http://dx.doi.org/10.1371/journal.pone.0030802.
57. Sumpter R, Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79:2689-2699. http://dx.doi.org/10.1128/JVI.79.5.2689-2699.2005.
58. Gouttenoire J, Penin F, Moradpour D. 2010. Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Rev Med Virol 20: 117-129. http://dx.doi.org/10.1002/rmv.640.
59. Yu CY, Chang TH, Liang JJ, Chiang RL, Lee YL, Liao CL, Lin YL. 2012. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog 8:e1002780. http://dx.doi.org/10.1371/journal.ppat.1002780.
60. Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR. 2008. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 26: 1019-1027. http://dx.doi.org/10.1038/nbt.1490.